Case Study: Dermatology Biopharma achieves real-time safety oversight with Veeva Systems

A Growing Dermatology Biopharma Improves Oversight with In-House Drug Safety

Dermatology Biopharma, a growing biopharma that launched its first commercial product in 2022, needed better oversight of its safety operations while still relying on outsourced pharmacovigilance activities. To regain control of its data and improve audit readiness, the company brought drug safety in-house using Veeva Systems’ Veeva Safety platform.

Veeva Systems implemented a centralized safety database that gave the three-person PV team real-time visibility, faster reporting, and tighter vendor oversight. As a result, Dermatology Biopharma cut PADER reporting time from 30 days to two weeks, a 50% improvement, and set up its safety database in just a few months to support an upcoming PMDA approval.